New Survey Finds Chronic Pain Treatments Are Failing Sufferers Across Europe
dinsdag 29-01-2013 10:35
Dit is een origineel bericht van PR Newswire
PARIS, January 29, 2013 /PRNewswire/ --
Organizations Team up to Raise awareness and Make a Call to Action for European Governments to Develop Comprehensive Chronic Pain Treatment Programs
Boston Scientific Corporation today released results of a survey of more than 1,000 chronic pain sufferers across Europe that suggest millions of patients there continue to suffer on a daily basis even after trying several treatment options. "The Painful Truth Survey: The State of Pain Management in Europe," sponsored by Boston Scientific and supported by third party groups, including Action on Pain UK, the Spanish Pain Association (EFHRE Sine Dolore) and the German Pain League (Deutsche Schmerzliga), found that more than a third of sufferers still struggle with routine daily tasks affecting their work and personal lives, their relationships and the ability to care for their children. The organizations involved with the Painful Truth Survey call for governments in all European countries to develop national plans for chronic pain management that go beyond the traditional diagnosis and treatment routes.
Chronic pain sufferers and healthcare professionals do not always have the necessary information and understanding of available treatments options. The results show one fifth of those surveyed have a chronic pain diagnosis that may be treated or managed with innovative treatment options such as rechargeable Spinal Cord Stimulation (SCS). However, despite availability across Europe, two thirds of sufferers have never heard of the treatment.
"Many patients see their doctor several times before they are referred on to a specialist and this can be very frustrating for someone who is living with constant pain on a day to day basis," said Harry Kletzko, vice president of the German Pain League. "Pain really impacts how you live your life, even with simple tasks such as getting out of bed, which can become extremely difficult. Because chronic pain is so hard to describe, it's hard for someone who is not experiencing it to actually understand where the pain is and how it affects patients."
In Europe, chronic pain is one of the most common conditions for which people seek medical attention. About a third of sufferers indicate their chronic pain has lowered their household income by about 31 percent (averaging EUR5,000 annually)and the condition itself costs the European healthcare system as much as EUR300 billion a year. An estimated 90 percent of this can be attributed to indirect costs such as lost productivity, social security and welfare payments.
"For many patients, conventional medication or surgery is not the answer and we need to be exploring how best to use innovative and cost-effective technologies as they emerge," said Dr. Simon Thomson, Consultant in Pain Medicine and Neuromodulation at Basildon and Thurrock University Hospitals NHS Foundation Trust, United Kingdom. "In the longer term, SCS may not only improve the sufferer's pain, but also reduce the burden on the health economy by getting the right treatment to the right individual at the right time."
Treatment options such as rechargeable SCS may help some patients manage their chronic pain, possibly reducing the need for daily medicinal therapy, and relieve subsequent pressure on healthcare systems. Studies have shown that the cost of treating patients with SCS are recuperated in one to three years in comparison to conventional therapies, due to a reduction in healthcare resources such as drug therapy and repeat hospitalizations.
Along with urging governments across Europe to take action and address issues involving pain, survey organizers also call for better access to innovative treatment options that may not only benefit patients, but may also benefit health economies through demonstrated cost effectiveness.
For further information and access to the full report, images and videos please visit http://www.epresspack.net/mnr/new-survey-finds-chronic-pain-treatments-are-failing-sufferers-across-europe .
About Boston Scientific Neuromodulation
Boston Scientific Neuromodulation is an innovation leader in implantable pain management technology. Through its investments in technology, clinical science and world-class service, Boston Scientific Neuromodulation is committed to making life smoother for physicians and patients.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit us at http://www.bostonscientific-international.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the Painful Truth Survey results, benefits of rechargeable spinal cord stimulation, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
CONTACT: CONTACTS: Sejal Sachdev, Weber Shandwick, T: + 44(0)20-7067-0587,email@example.com; Nathalie Verin, Health Economics & PublicAffairs Manager, Boston Scientific, M: +44(0)7785-510429, VerinN@bsci.com;Simonetta Balbi, PR and Corporate Communication EMEA, Boston Scientific, M:+39-3387936422, T: +39-0106060281, Balbis@bsci.com